Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)

Kosiborod, Mikhail; Cavender, Matthew A.; Fu, Alex Z.; Wilding, John P.; Khunti, Kamlesh; Holl, Reinhard; Norhammar, Anna; Birkeland, Kare I.; Jorgensen, Marit Eika; Thuresson, Marcus; Arya, Niki; Bodegard, Johan; Hammar, Niklas; Fenici, Peter; CVD-REAL Investigators Study Grp

Erstveröffentlichung

2017

Metadata only
Search for full text

Wissenschaftlicher Artikel

Authors

Kosiborod, Mikhail

Cavender, Matthew A.

Fu, Alex Z.

Wilding, John P.

Khunti, Kamlesh

et al.

Faculties

Medizinische Fakultät

Institutions

Institut für Epidemiologie und Medizinische Biometrie

Published in

Circulation ; 136 (2017), 3. - S. 249+. - ISSN 0009-7322. - eISSN 1524-4539

Link to publication

https://dx.doi.org/10.1161/CIRCULATIONAHA.117.029190

Funding information

AstraZeneca

Keywords

canagliflozin; dapagliflozin; death; diabetes mellitus; empagliflozin; heart failure; sodium glucose transporter 2; diabetes-mellitus; mortality; association; metaanalysis; prevalence; mechanisms; diagnosis; accuracy; register; disease

Dewey Decimal Group

DDC 610 / Medicine & health

Metadata

Show full item record